Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study
Author:
Funder
Biogen
Publisher
Springer Science and Business Media LLC
Subject
Clinical Neurology,Neurology
Link
http://link.springer.com/article/10.1007/s00415-017-8544-6/fulltext.html
Reference20 articles.
1. Kieseier BC, Calabresi PA (2012) PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis. CNS Drugs 26:205–214
2. Baker DP, Pepinsky RB, Brickelmaier M et al (2010) PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. J Interferon Cytokine Res 30:777–785
3. Calabresi PA, Kieseier BC, Arnold DL, ADVANCE Study Investigators et al (2014) Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 13:657–665
4. Kieseier BC, Arnold DL, Balcer LJ et al (2015) Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler 21:1025–1035
5. Arnold DL, Matthews PM (2002) MRI in the diagnosis and management of multiple sclerosis. Neurology 58(8 Suppl 4):S23–S31
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY);Multiple Sclerosis and Related Disorders;2024-10
2. Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN;Multiple Sclerosis and Related Disorders;2022-01
3. Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010;CNS Drugs;2018-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3